JUBILANT PHARMOVA LIMITED
Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, distribution, sale, and marketing of generic formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, antibiotics, and multispecialty. The Contract Research Development and Manufacturing Organisation segment offers drug discovery services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment provides patient-focused biopharmaceutical services to address unmet medical needs in oncology and autoimmune diseases. The company serves pharmaceutical, biotech, group purchasing organisations, allergists, and hospitals sectors. It sells its products through a network of dealers and distributors. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is based in Noida, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Maintains healthy dividend payout of 252.0%
Concerns1
- Low interest coverage ratio of 0.6x
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ746.00 Cr | β | βΉ19.00 Cr | β | β | 0.8% | -5.0% | -40.6% |
| Mar 2024 | βΉ785.00 Cr | β | βΉ32.00 Cr | β | β | 1.3% | -3.1% | -36.0% |
| Mar 2023 | βΉ810.00 Cr | β | βΉ50.00 Cr | β | β | 2.1% | 11.6% | -37.5% |
| Mar 2022 | βΉ726.00 Cr | β | βΉ80.00 Cr | β | β | 3.3% | -73.2% | -62.6% |
| Mar 2021 | βΉ2.71 K Cr | β | βΉ214.00 Cr | β | β | 16.7% | -13.7% | -33.3% |
| Mar 2020 | βΉ3.14 K Cr | β | βΉ321.00 Cr | β | β | 12.3% | -8.7% | 116.9% |
| Mar 2019 | βΉ3.44 K Cr | β | βΉ148.00 Cr | β | β | 6.3% | 4.0% | -43.7% |
| Mar 2018 | βΉ3.31 K Cr | β | βΉ263.00 Cr | β | β | 11.7% | 32.7% | 232.9% |
| Mar 2017 | βΉ2.49 K Cr | β | βΉ79.00 Cr | β | β | 3.9% | -6.2% | 8.2% |
| Mar 2016 | βΉ2.66 K Cr | β | βΉ73.00 Cr | β | β | 3.6% | -16.3% | -64.4% |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 383 |
| Total Expenses | 339 |
| EBIT / Operating Profit | 44 |
| OPM % | 12% |
| Other Income | 76 |
| Finance Costs | 16 |
| Depreciation & Amortisation | 18 |
| Profit Before Tax | 86 |
| Tax % | - |
| Net Profit / PAT | 18 |
| EPS (βΉ) | 1.14 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| JUBILANT PHARMOVA LIMITEDthis co. | βΉ16.58 K Cr | βΉ746.00 Cr | 0.00 | 7.38 | 140.36 | -5.0% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |